Egetis Therapeutics

Share Issue/Capital Change • Dec 30, 2025

Change in the number of ordinary shares and votes in Egetis Therapeutics

Stockholm, December 30, 2025. The number of ordinary shares and votes in Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (Nasdaq Stockholm: EGTX) has increased during the month of December as a result of the exercise of options under the three-year incentive program adopted at the 2022 Annual General Meeting. The total number of shares in the Company is unchanged at 424,161,938, but the number of ordinary shares has increased by 734, from 395,161,938 to 395,162,672 and the number of C-shares has decreased by 734, from 29,000,000 to 28,999,266. The total number of votes in the Company has increased by 660.6 votes, from 398,061,938 to 398,062,598.6. The share capital is unchanged at approximately SEK 22,324,320.854470.

For further information, please contact:

Karl Hård, Head of Investor Relations & Business Development +46 (0) 733 011 944 karl.hard@egetis.com

This information is information that Egetis Therapeutics is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2025-12-30 08:00 CET.

About Egetis Therapeutics

Egetis Therapeutics is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment.

The Company's lead drug candidate Emcitate® (tiratricol) is developed for the treatment of patients with monocarboxylate transporter 8 (MCT8) deficiency, a highly debilitating rare disease with no available treatment. In February 2025 the European Commission approved Emcitate® as the first and only treatment for MCT8 deficiency in EU. Egetis initiated the launch of Emcitate® in Germany on May 1, 2025. Emcitate® (tiratricol) is not approved in the USA.

The Company initiated a rolling New Drug Application (NDA) for Emcitate® (tiratricol) in the USA in December 2025 targeting a complete NDA submission in early 2026 and anticipated completion of FDA's review process in the third quarter of 2026. Based on feedback from the FDA, the NDA for Emcitate® (tiratricol) for treatment of MCT8 deficiency will be based on currently available clinical data from Triac Trial I, Triac Trial II, ReTRIACt, EMC Cohort Study, EMC Survival Study and the US Expanded Access Program.

Tiratricol holds Orphan Drug Designation (ODD) for MCT8 deficiency and resistance to thyroid hormone beta (RTH-beta) in the US and the EU. MCT8 deficiency and RTH-beta are two distinct indications, with no overlap in patient populations. Tiratricol has been granted Breakthrough Therapy Designation and Rare Pediatric Disease Designation (RPDD) by the FDA, which gives Egetis the opportunity to receive a Priority Review Voucher (PRV) in the US, after approval.

The drug candidate Aladote® (calmangafodipir) is a first in class drug candidate developed to reduce the risk of acute liver injury associated with paracetamol (acetaminophen) overdose. A proof of principle study has been successfully completed. The design of a pivotal Phase IIb/III study (Albatross), with the purpose of applying for market approval in the US and Europe, has been finalized following interactions with the FDA, EMA and MHRA. The development program for Aladote® has been parked until Emcitate® marketing authorization submissions for MCT8 deficiency have been completed. Aladote® has been granted ODD in the US and in the EU.

Egetis Therapeutics is listed on the Nasdaq Stockholm main market (Nasdaq Stockholm: EGTX). For more information, see www.egetis.com

Attachments

Change in the number of ordinary shares and votes in Egetis Therapeutics